DUBLIN--(BUSINESS WIRE)--Jul 10, 2018--The "Investigation Report on Chinese Enoxaparin Sodium Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Low-molecular-weight heparin preparations are gradually replacing unfractionated heparin preparations because of wider clinical applications. The main product of low-molecular-weight heparin preparations is Enoxaparin Sodium which was originally developed by Aventis (merged with Sanofi later) and approved to be sold in the trade name of Lovenox in 1993. Sanofi's Enoxaparin Sodium Injection was approved by FDA in Oct. 2004, and entered the Chinese market in the beginning of 2005 with a continuous growth in market size. Its sales value exceeded CNY 300 million in 2017.

Generic drugs also takes up some market share because the average price of Sanofi's products is comparatively high. Many pharmaceutical enterprises in China have obtained the production permit for Enoxaparin Sodium injection.

This market research shows that the Chinese market is dominated by Sanofi. Other major market players include Hangzhou Jiuyuan Gene Engineering Co., Ltd., Shenzhen Techdow Pharmaceutical Co., Ltd., etc.

In 2017, the top 5 manufacturers took up over 90% market share by sales value, with Sanofi's market share reaching approximately 80%. Sanofi's market share is gradually flowing to domestic enterprises because of high average price. It is estimated that Sanofi will have ever smaller market share in the coming years with more Enoxaparin Sodium manufacturers entering the market in China.

According to research, as China's population ages, the incidence of vascular embolic disease continues to rise. At the same time, as the incidence of ESRD in China continues to rise, the number of people receiving hemodialysis is also rising. All these factors have driven the growth of the Enoxaparin Sodium market. There is still a large growth potential for the Chinese Enoxaparin Sodium market.

Topics Covered

Incidence of Thrombosis in China Development History of Enoxaparin Sodium in China Sales of Enoxaparin Sodium in China Prices of Enoxaparin Sodium in China Major Enoxaparin Sodium Manufacturers in China Prospects of Chinese Enoxaparin Sodium Market

Companies Featured

Beijing SL Pharmaceutical Co., Ltd. Changzhou Qianhong Bio-pharma Co., Ltd. Chengdu Baiyu Pharmaceutical Co., Ltd. Hangzhou Jiuyuan Gene Engineering Co., Ltd. Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. Sanofi Shenzhen Techdow Pharmaceutical Co., Ltd. Suzhou Erye Pharmaceutical Co., Ltd

Key Topics Covered

1 Relevant Concepts of Enoxaparin Sodium

2 Analysis on Sales of Enoxaparin Sodium in China, 2013-2017

3 Major Enoxaparin Sodium Manufacturers in China, 2013-2017

4 Prices of Enoxaparin Sodium in China, 2017-2018

5 Prospects of Chinese Enoxaparin Sodium Market, 2018-2022

Selected Charts

For more information about this report visit https://www.researchandmarkets.com/research/72x28c/chinese?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180710005527/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Cardiovascular Drugs

KEYWORD: ASIA PACIFIC CHINA

INDUSTRY KEYWORD: HEALTH CARDIOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/10/2018 08:25 AM/DISC: 07/10/2018 08:25 AM

http://www.businesswire.com/news/home/20180710005527/en